BioSpace News Archive

Partly because it’s an election year and partly because, well, drugs can be expensive, the topic of drug pricing is a hot-button issue.

Nourianz (istradefylline) was given the thumbs-up as an add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease who experience “OFF” episodes.

It takes on average five years before the confirmatory trial is even started.

According to “people familiar with the matter,” the company and its owners, the Sackler family, are plotting out a way to end the vast number of lawsuits filed against the company over its marketing practices for OxyContin and other opioid products.

The two companies struck a strategic collaboration and option agreement to harness the power of Immatics’ T-Cell Receptor Engineered T-cell Therapy programs and aim them at solid tumors.

Not only can we humanize with storytelling; we can use stories to connect.

ASLAN Pharmaceuticals today announced that a late-breaking abstract detailing results from a phase 2 study of varlitinib in patients with advanced or metastatic biliary tract cancer in China has been accepted for oral presentation at the upcoming 2019 Chinese Society of Clinical Oncology (CSCO) in Xiamen, China on 19 September 2019.

Paper By Company’s Scientific Co-Founder Published in Cancer Discovery

Great Bay Bio is pleased to announce that following the successful establishment of the 3D Advisory Board in the middle of this month, the Science Sub-Committee welcomes another new key member, Dr. Mark McHale, to the team.

Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.